Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.
Werner-Klein M, Grujovic A, Irlbeck C, Obradović M, Hoffmann M, Koerkel-Qu H, Lu X, Treitschke S, Köstler C, Botteron C, Weidele K, Werno C, Polzer B, Kirsch S, Gužvić M, Warfsmann J, Honarnejad K, Czyz Z, Feliciello G, Blochberger I, Grunewald S, Schneider E, Haunschild G, Patwary N, Guetter S, Huber S, Rack B, Harbeck N, Buchholz S, Rümmele P, Heine N, Rose-John S, Klein CA.
Werner-Klein M, et al. Among authors: kirsch s.
Nat Commun. 2020 Oct 5;11(1):4977. doi: 10.1038/s41467-020-18701-4.
Nat Commun. 2020.
PMID: 33020483
Free PMC article.